Adicet Bio, Inc.

Adicet Bio reported a net loss of $21.4 million for Q2 2026, a significant improvement from $31.2 million in Q2 2025. For the first six months of 2026, the net loss was $41.6 million, down from $59.4 million in the prior year, driven by reduced operating expenses. The company expects its cash, cash equivalents, and short-term investments, totaling $118.2 million as of June 30, 2026, to fund operations for at least the next twelve months, supported by recent equity financings.

Adicet Bio reported a net loss of $21.4 million, or $1.99 per share, for Q2 2026, an improvement from $31.2 million in Q2 2025. The company anticipates a comprehensive Phase 1 clinical update for prula-cel in LN/SLE in Q3 2026 and plans a regulatory filing for ADI-212 in mCRPC in Q3 2026. Additionally, Adicet Bio appointed Lloyd Klickstein as Interim Chief Medical Officer and expects its cash and investments of $118.2 million to fund operations into the second half of 2027.

Adicet Bio, Inc. filed an amended Annual Report on Form 10-K/A for the year ended December 31, 2025. This amendment corrects an inadvertent omission in Item 9A "Controls and Procedures" from the original filing. The updated disclosure now includes statements from the company's principal executive and financial officers, confirming that disclosure controls and procedures, as well as internal control over financial reporting, were effective as of December 31, 2025.

Adicet Bio reported a reduced net loss of $20.2 million for Q1 2026, an improvement from $28.2 million in Q1 2025, with EPS improving to $(1.88) from $(4.96). This reduction was primarily driven by significant decreases in both research and development and general and administrative expenses. The company maintains sufficient liquidity, with cash, cash equivalents, and short-term investments totaling $137.6 million, expected to fund operations for at least the next twelve months, supported by recent equity offerings.

Adicet Bio reported a net loss of $20.2 million for the first quarter ended March 31, 2026, an improvement from $28.2 million in the same period last year, with R&D expenses decreasing to $17.5 million. The company holds $137.6 million in cash, cash equivalents, and short-term investments, projecting a cash runway into the second half of 2027. Operationally, Adicet Bio anticipates a Phase 1 clinical update for prula-cel in autoimmune diseases in mid-2026 and expects FDA interaction on pivotal trial design in Q2 2026. Additionally, a regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer is planned for Q3 2026, with Phase 1 enrollment expected in Q4 2026.

Adicet Bio, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026, at 5:00 p.m. Eastern Time. Stockholders of record as of April 21, 2026, are invited to vote on the election of three Class II directors, a non-binding advisory resolution on executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for 2026. Proxy materials were made available on or about April 29, 2026.

Adicet Bio, Inc. filed the form of a Pre-Funded Warrant to Purchase Common Stock, outlining the terms for holders to acquire shares. The warrants have an exercise price of $0.0001 per share and are exercisable via a cashless mechanism. Key provisions include adjustments for corporate events and a beneficial ownership limitation of 9.99%, which can be increased to 19.99% by the holder.